

Lot No.: **78E**

Lot-specific information

***Olerup* SSP[®] HLA-B*5111N**

Product number:	101.851-12u – without <i>Taq</i> polymerase
Lot number:	78E
Expiry date:	2010-June-01
Number of tests:	12
Number of wells per test:	2
Storage - pre-aliquoted primers:	dark at -20°C
- PCR Master Mix:	-20°C
- Adhesive PCR seals	RT
- Product Insert	RT

This Product Description is only valid for Lot No. 78E.

Changes in revision R01 compared to R00:

1. Alleles amplified by primer mixes 1 and 2 in the Specificity Table have been corrected.

Lot No.: **78E**

Lot-specific information

PRODUCT DESCRIPTION

HLA-B*5111N SSP subtyping

CONTENT

The primer set contains 5'- and 3'-primers for identifying the HLA-B*5111N allele.

PLATE LAYOUT

Each test consists of 2 PCR reactions in an 8 well cut PCR plate. Each 8 well cut PCR plate contains four tests.

1	2	1	2	1	2	1	2
---	---	---	---	---	---	---	---

The 8 well cut PCR plate is marked with the Lot No. '78E'.

Well No. 1 is marked with the Lot No. '78E'.

The PCR plates are heat-sealed with a PCR-compatible foil.

Please note: When removing each 8 well PCR plate, make sure that the remaining plates stay sealed. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

INTERPRETATION

The interpretation of HLA-B*5111N SSP subtypings will be influenced by the B**0832, the B*18, the B*35, the B*3708, two B*38, two B*39, the B*4406, the B*51, the B*53 and most B*78 alleles..

UNIQUELY IDENTIFIED ALLELES

The HLA-B*5111N allele will give rise to a unique amplification pattern by the primers in the HLA-B*5111N kit¹.

¹HLA-A alleles listed on the IMGT/HLA web page 2008-April-08, release 2.21.0, www.ebi.ac.uk/imgt/hla.

Lot No.: **78E**

Lot-specific information

SPECIFICITY TABLE

HLA-B*5111N SSP subtyping

Specificities and sizes of the PCR products of the 2 primer mixes used for HLA-B*5111N SSP subtyping

Primer Mix	Size of spec. PCR product ¹	Size of control band ²	Amplified HLA-B alleles
1³	95 bp	800 bp	0832, 180101-1811, 1813-1815, 1817N-1829, 350101-350902, 3511, 3512, 351401-3515, 3517, 3518, 352001-3524, 3527, 3529-3545, 3548, 3550-3562, 3564-356802, 3570-3572, 3574-3579, 3581-3588, 3708, 3806, 3807, 391901-391902, 4406, 510101-512402, 5126-5146, 5148-5155, 530101-5316, 7801-7804
2	494 bp	1070 bp	5111N

¹Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-B*5111N SSP typings. Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers. PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings. PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherent feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

²The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 1070 base pairs, for most wells, or a band of 800 base pairs, for some wells. Well number 1 contains the primer pair giving rise to the shorter, 800 bp, internal positive control band in order to help in the correct orientation of the HLA-B*5111N subtyping.

³Specific PCR fragments shorter than 150 base pairs have a lower intensity than longer PCR bands.

Lot No.: **78E**

Lot-specific information

INTERPRETATION TABLE		
HLA-B*5111N SSP typing		
	Well	
	1	2
Length of spec.	95	495
PCR product		
Length of int.	800	1070
pos. control¹		
5'-primer(s)²	206	3rd I
	5'-gAC ^{3'}	5'-CTT ^{3'}
3'-primer(s)³	259	620
	5'-gTT ^{3'}	5'-ggg ^{3'}
Well No.	1	2
HLA-B allele		
B*5111N	1	2
*0832, 180101-1811, 1813-1815, 1817N-1829, 350101-350902, 3511, 3512, 351401-3515, 3517, 3518, 352001-3524, 3527, 3529-3545, 3548, 3550-3562, 3564-356802, 3570-3572, 3574-3579, 3581-3588, 3708, 3806, 3807, 391901-391902, 4406, 510101-5110, 5112-512402, 5126-5146, 5148-5155, 530101-5316, 7801-7804	1	
HLA-B allele		
Well No.	1	2

¹The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 1070 base pairs, for most wells, or a band of 800 base pairs, for some wells.

Well number 1 contains the primer pair giving rise to the shorter, 800 bp, internal positive control band in order to help in the correct orientation of the HLA-B*5111N subtyping. .

²The nucleotide position, in the 2nd exon or 3rd intron, matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

³The nucleotide position, in the 2nd or 3rd exons, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

Lot No.: **78E**

Lot-specific information

CELL LINE VALIDATION SHEET						
HLA-B*5111N SSP kit						
					Well	
					1	2
				Lot No.:	200848101	200848102
	IHWC cell line		HLA-B			
1	9001	SA	*0702		-	-
2	9280	LK707	*5201	*7301	-	-
3	9011	E4181324	*52011		-	-
4	9275	GU373	*1510	*5301	+	-
5	9009	KAS011	*3701		-	-
6	9353	SM	*3901	*5101	-	-
7	9020	QBL	*1801		+	-
8	9007	DEM	*5701		-	-
9	9026	YAR	*3801		-	-
10	9107	LKT3	*5401		-	-
11	9051	PITOUT	*4403		-	-
12	9052	DBB	*5701		-	-
13	9067	BTB	*2705		-	-
14	9071	OLGA	*1501	*1520	-	-
15	9075	DKB	*4001		-	-
16	9037	SWEIG007	*4002		-	-
17	9008	WILJON	*1801		+	-
18	9257	32367	*1401	*5601	-	-
19	9038	BM16	*1801		+	-
20	9059	SLE005	*4001		-	-
21	9064	AMALA	*1501		-	-
22	9056	KOSE	*3503		+	-
23	9124	IHL	*4002	*5602	-	-
24	9035	JBUSH	*3801		-	-
25	9049	IBW9	*1402		-	-
26	9285	WT49	*5801		-	-
27	9191	CH1007	*0705	*5101	+	-
28	9320	BEL5GB	*4402	*4403	-	-
29	9050	MOU	*4403		-	-
30	9021	RSH	*4201		-	-
31	9019	DUCAF	*1801		+	-
32	9297	HAG	*4102		-	-
33	9098	MT14B	*4001		-	-
34	9104	DHIF	*3801		-	-
35	9302	SSTO	*4402		-	-
36	9024	KT17	*1501	*3501	+	-
37	9065	HHKB	*0702		-	-
38	9099	LZL	*1501		-	-
39	9315	CML	*0801	*2705	-	-
40	9134	WHONP199	*1302	*4601	-	-
41	9055	H0301	*1402		-	-
42	9066	TAB089	*4601		-	-
43	9076	T7526	*4601		-	-
44	9057	TEM	*3801		-	-
45	9239	SHJO	*4201	*5001	-	-
46	9013	SCHU	*0702		-	-
47	9045	TUBO	*5101		+	-
48	9303	TER-ND	*3501	*4403	+	-

Lot No.: **78E**

Lot-specific information

CERTIFICATE OF ANALYSIS

Olerup SSP® HLA-B*5111N SSP

Product number: 101.851-12u – without *Taq* polymerase
Lot number: 78E
Expiry date: 2010-June-01
Number of tests: 12
Number of wells per test: 2

Well specifications:

Well No.	Production No.
1	2008-481-01
2	2008-481-02

The specificity of each primer solution of the kit has been tested against 48 well characterized IHWC cell line DNAs.

Results: No false positive or false negative amplifications were obtained.

Date of approval: 2009-May-27

Approved by:

Quality Control, Supervisor

Lot No.: **78E**

Lot-specific information

Declaration of Conformity

Product name: *Olerup* SSP® HLA-B*5111N
Product number: 101.851-12u
Lot number: 78E

Intended use: HLA-B*5111N histocompatibility testing

Manufacturer: *Olerup* SSP AB
Hasselstigen 1
SE-133 33 Saltsjöbaden, Sweden
Phone: +46-8-717 88 27
Fax: +46-8-717 88 18

We, *Olerup* SSP AB, hereby declare that this product, to which this Declaration of Conformity relates is in conformity with the following Standard(s) and other normative document(s) ISO 9001:2000 and ISO 13485:2003, following the provisions of the 98/79/EC Directive on *in vitro* diagnostic medical devices, Annex II List B, as transposed into the national laws of the Member States of the European Union.

The Technical Documentation File is maintained at *Olerup* SSP AB, Hasselstigen 1, SE-133 33 Saltsjöbaden, Sweden.

The Authorized Representative located within the Community is: *Olerup* SSP AB.

Notified Body: Lloyd's Register Quality Assurance Limited, Hiramford, Middlemarch Office Village, Siskin Drive, Coventry CV3 4FJ, United Kingdom. (Notified Body number: 0088.)

Saltsjöbaden, Sweden
2009-May-27

Olle Olerup
Managing Director

Lot No.: **78E**

Lot-specific information

ADDRESSES:

Manufacturer:

Olerup SSP AB, Hasselstigen 1, SE-133 33 Saltsjöbaden, Sweden.

Tel: +46-8-717 88 27

Fax: +46-8-717 88 18

E-mail: info-ssp@olerup.com

Web page: <http://www.olerup.com>

Distributed by:

Olerup GmbH, Löwengasse 47 / 6, AT-1030 Vienna, Austria.

Tel: +43-1-710 15 00

Fax: +43-1-710 15 00 10

E-mail: support-at@olerup.com

Web page: <http://www.olerup.com>

Olerup Inc., 901 S. Bolmar St., Suite R, West Chester, PA 19382

Tel: 1-877-OLERUP1

Fax: 610-344-7989

E-mail: info.us@olerup.com

Web page: <http://www.olerup.com>

For information on *Olerup* SSP distributors worldwide, contact **Olerup GmbH**.